Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
In this guide, well explore nutrition strategies to optimize your results and address common side effects of GLP-1 medications
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials
While bariatric surgery achieved more substantial weight loss, GLP-1 RA therapy was associated with more favorable overall clinical outcomes in patients with idiopathic intracranial hypertension
Insoluble fiber adds bulk and keeps digestion moving
A weight loss of 2.73.7 kg over 52 weeks has been associated with its use in people with T2D [73, 74]
